期刊
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 56
卷 56, 期 -, 页码 23-40出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-010715-103440
关键词
oncogenes; cancer drug targets; phosphatases; transcription factors; RAS
资金
- NATIONAL CANCER INSTITUTE [R21CA191944] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI068021] Funding Source: NIH RePORTER
- NCI NIH HHS [CA191944] Funding Source: Medline
- NIAID NIH HHS [U19 AI068021] Funding Source: Medline
Cancer, more than any other human disease, now has a surfeit of potential molecular targets poised for therapeutic exploitation. Currently, a number of attractive and validated cancer targets remain outside of the reach of pharmacological regulation. Some have been described as undruggable, at least by traditional strategies. In this article, we outline the basis for the undruggable moniker, propose a reclassification of these targets as undrugged, and highlight three general classes of this imposing group as exemplars with some attendant strategies currently being explored to reclassify them. Expanding the spectrum of disease-relevant targets to pharmacological manipulation is central to reducing cancer morbidity and mortality.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据